Article
Rheumatology
Ilaria Maccora, Niccolo Lombardi, Giada Crescioli, Alessandra Bettiol, Roberto Bonaiuti, Ilaria Pagnini, Valerio Maniscalco, Edoardo Marrani, Maria Vincenza Mastrolia, Claudia Ravaldi, Rita Consolini, Marco Cattalini, Alfredo Vannacci, Gabriele Simonini
Summary: This study aimed to evaluate the long-term efficacy and safety of switching from originators ETA and ADA to their biosimilars in children with JIA. The results showed no significant difference in efficacy and safety between the originators and biosimilars at 3, 6, and 12 months after the switch.
Article
Ophthalmology
Noopur Kumar, Turid Follestad, H. Nida Sen, Dordi Austeng
Summary: The study compared the efficacy of biosimilar infliximab to originator infliximab in treating chronic non-infectious uveitis, finding no significant differences in achieving quiescence or flare rates between the two treatments.
AMERICAN JOURNAL OF OPHTHALMOLOGY
(2021)
Article
Pharmacology & Pharmacy
Anat Fisher, Jason D. Kim, Colin Dormuth
Summary: This study found marginal changes in health services utilization after mandatory switching patients from originator to biosimilar insulin glargine in British Columbia, Canada, without detecting signals of negative health impacts on patients.
CLINICAL THERAPEUTICS
(2022)
Article
Pharmacology & Pharmacy
Anat Fisher, Jason D. Kim, Colin Dormuth
Summary: This study monitored early changes in health services utilization after a mandatory policy switch from originator to biosimilar insulin glargine in British Columbia, Canada. The findings in the first year of the policy showed increases in insulin glargine and oral antidiabetic medication use, as well as outpatient visits. Likelihood ratios above the threshold of 7.1 were detected for these outcomes, suggesting a possible policy impact.
CLINICAL THERAPEUTICS
(2022)
Article
Multidisciplinary Sciences
Hugo Jourdain, Lea Hoisnard, Emilie Sbidian, Mahmoud Zureik
Summary: This study assessed the penetration rates of infliximab, etanercept, and adalimumab biosimilars using data from the French National Health Data System. The study found that biosimilar use was higher in rheumatology and the initiation rate of biosimilars increased rapidly after market arrival.
SCIENTIFIC REPORTS
(2022)
Article
Rheumatology
Andrew R. Melville, Md Yuzaiful Md Yusof, John Fitton, Leticia Garcia-Montoya, Lynda Bailey, Shouvik Dass, Paul Emery, Maya H. Buch, Benazir Saleem
Summary: The study evaluated the impact of non-medical switch from rituximab originator (RTX-O) to biosimilar (RTX-B) in patients with rheumatoid arthritis. The results showed that non-medical switch to RTX-B was largely effective, with factors like comorbidities, previous biologic DMARDs, and RTX-O treatment history influencing switch decisions.
Article
Gastroenterology & Hepatology
Lauranne A. A. P. Derikx, Heather W. Dolby, Nikolas Plevris, Laura Lucaciu, Caitlin S. Rees, Mathew Lyons, Spyros Siakavellas, Nathan Constantine-Cooke, Philip Jenkinson, Shanna Su, Claire O'Hare, Laura Kirckpatrick, Lynne M. Merchant, Colin Noble, Ian D. Arnott, Gareth-Rhys Jones, Charlie W. Lees
Summary: The study found that switching from the ADA originator to SB5 is effective and safe for patients with inflammatory bowel disease. Over 12 months of follow-up, most patients remained stable on SB5 treatment. The most frequently reported adverse event was injection site pain.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Gastroenterology & Hepatology
Maria Jose Casanova, Oscar Nantes, Pilar Varela, Milagros Vela-Gonzalez, Montserrat Rivero, Olivia Sierra-Gabarda, Sabino Riestra, Manuel Barreiro-de Acosta, Maria del Mar Martin-Rodriguez, Carla Jerusalen Gargallo-Puyuelo, Cristina Reygosa, Roser Munoz, Irene Garcia de la Filia-Molina, Andrea Nunez-Ortiz, Lilyan Kolle, Margalida Calafat, Jose Maria Huguet, Eva Iglesias-Flores, Teresa de Jesus Martinez-Perez, Orencio Bosch, Jose Maria Duque-Alcorta, Santiago Frago-Larramona, Manuel Van Domselaar, Victor Manuel Gonzalez-Cosano, Luis Bujanda, Saioa Rubio, Alejo Mancebo, Beatriz Castro, Santiago Garcia-Lopez, Ruth de Francisco, Laura Nieto-Garcia, Viviana Laredo, Ana Gutierrez-Casbas, Francisco Mesonero, Eduardo Leo-Carnerero, Fiorella Canete, Lucia Ruiz, Beatriz Gros, Maria del Moral-Martinez, Cristina Rodriguez, Maria Chaparro, Javier P. Gisbert
Summary: This study compared the treatment persistence, clinical efficacy, and safety outcomes in inflammatory bowel disease patients who maintained the adalimumab originator versus those who switched to adalimumab biosimilar. The results showed that switching to adalimumab biosimilar did not show any significant differences in treatment persistence, clinical efficacy, and safety outcomes compared to maintaining the originator.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Dermatology
Nikolai Loft, Alexander Egeberg, Mads Kirchheiner Rasmussen, Lars Erik Bryld, Christoffer Valdemar Nissen, Tomas Norman Dam, Kawa Khaled Ajgeiy, Lars Iversen, Lone Skov
Summary: This cohort study from Denmark assessed the outcomes of patients switching from adalimumab originator to adalimumab biosimilars, and found that the switch was not associated with drug retention.
Article
Medicine, General & Internal
Claire T. Deakin, Geoffrey O. Littlejohn, Hedley Griffiths, Sabina Ciciriello, Catherine O'Sullivan, Tegan Smith, Peter Youssef, Paul Bird
Summary: This study aimed to compare the effectiveness of ETN originator and ETN biosimilar as first-line treatment in RA patients and explore the potential cost-savings in Australia. The results showed similar treatment persistence between the two drugs and significant cost-savings for the Australian Government with the introduction of the ETN biosimilar.
INTERNAL MEDICINE JOURNAL
(2023)
Article
Medicine, General & Internal
Trinidad Montero-Vilchez, Carlos Cuenca-Barrales, Andrea Rodriguez-Tejero, Antonio Martinez-Lopez, Salvador Arias-Santiago, Alejandro Molina-Leyva
Summary: The study describes the clinical experience of switching from adalimumab originator to biosimilar and back again. Switching to biosimilar can lead to efficacy and adherence issues, while switching back to the original drug can resolve most problems, though some patients may lose confidence and discontinue treatment. Evaluating the benefit-risk ratio is important when switching HS patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Livia Lontai, Lorant Gonczi, Fruzsina Balogh, Nora Komlodi, Tamas Resal, Klaudia Farkas, Tamas Molnar, Pal Miheller, Petra A. Golovics, Eszter Schafer, Tamas Szamosi, Akos Ilias, Peter L. Lakatos
Summary: This study evaluated the medium-term clinical efficacy, drug sustainability, and safety of non-medical switches between adalimumab biosimilars. The results showed no significant difference in clinical remission rates or drug survival between non-medical switches from the originator to biosimilar ADA or between ADA biosimilars. The study concludes that clinical benefit can be sustained following non-medical switches in adalimumab-treated patients with inflammatory bowel disease.
DIGESTIVE AND LIVER DISEASE
(2022)
Article
Ophthalmology
Jordan D. Deaner, Sunil K. Srivastava, Rula A. Hajj-Ali, Careen Y. Lowder, Arthi G. Venkat, Kimberly Baynes, Sumit Sharma
Summary: This study investigated the frequency of ocular flares in patients with noninfectious uveitis switched from originator infliximab to biosimilar infliximab. Results showed that patients experienced more flares after switching to infliximab-abda, with a higher probability of flares within the first 90 days.
AMERICAN JOURNAL OF OPHTHALMOLOGY
(2021)
Article
Dermatology
Domenico Giordano, Alessandro Capalbo, Nazareno Gagliostro, Giusy Fedele, Charalampos G. Balampanos, Flavia Persechino, Vilma Bushati, Salvatore Ulisse, Severino Persechino, Giovanni Pellacani
Summary: The study aims to evaluate the bioequivalence between etanercept (ETN) and its biosimilar SB4 in a real-life setting. The results showed no significant differences between the two drugs in terms of efficacy, indicating that biosimilar drugs are a great opportunity to reduce healthcare costs and expand patient access to innovative treatments.
ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY
(2022)
Review
Oncology
Rosanne W. Meijboom, Helga Gardarsdottir, Toine C. G. Egberts, Thijs J. Giezen
Summary: The cumulative incidence of patients retransitioning from TNF-alpha inhibitor biosimilar to originator was estimated at 7.6%. Factors associated with retransitioning included patient disease diagnosis, disease stability, and treatment strategy implementation. Studies indicated that focusing on patients with stable disease and not providing the option for retransitioning at the introduction of biosimilars may reduce the risk of retransitioning.
Article
Rheumatology
T. Thomsen, B. A. Esbensen, M. L. Hetland, M. Aadahl
Summary: A randomized controlled trial aimed to reduce sedentary behaviour and increase light-intensity physical activity in patients with rheumatoid arthritis. The study found that patients who are less educated and have certain types of comorbidity are less motivated to participate in physical activity interventions. The findings can help improve recruitment processes and implementation of physical activity interventions in rheumatology clinical practice.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
M. A. Nielsen, D. Koster, S. Greisen, A. Troldborg, K. Stengaard-Pedersen, P. Junker, K. Horslev-Petersen, M. L. Hetland, M. Ostergaard, M. Hvid, H. Leffler, T. W. Kragstrup, B. Deleuran
Summary: The study found that patients with rheumatoid arthritis (RA) had persistently increased levels of galectin-3 (Gal-3) in their plasma, and changes in Gal-3 levels were associated with long-term disease activity. Gal-3 levels in synovial fluid were also significantly elevated. In vitro experiments showed that a Gal-3 inhibitor could reduce the activity of inflammatory cells.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
Daniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, Christian Dejaco, Maxime Dougados, Iain B. McInnes, Naveed Sattar, Tanja A. Stamm, Tsutomu Takeuchi, Michael Trauner, Desiree van der Heijde, Marieke Voshaar, Kevin L. Winthrop, Angelo Ravelli, Neil Betteridge, Gerd-Ruediger R. Burmester, Johannes W. J. Bijlsma, Vivian Bykerk, Roberto Caporali, Ernest H. Choy, Catalin Codreanu, Bernard Combe, Mary K. Crow, Maarten de Wit, Paul Emery, Roy M. Fleischmann, Cem Gabay, Merete Lund Hetland, Kimme L. Hyrich, Annamaria Iagnocco, John D. Isaacs, Joel M. Kremer, Xavier Mariette, Peter Merkel, Eduardo F. Mysler, Peter Nash, Michael T. Nurmohamed, Karel Pavelka, Gyula Poor, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Anja Strangfeld, Yoshiya Tanaka, Josef S. Smolen
Summary: This paper is an updated consensus document on the medical use of IL-6 pathway inhibition in the treatment of inflammatory diseases. The document provides comprehensive consensus statements based on systematic literature research and expert opinion, covering various aspects of IL-6 pathway inhibitors, including dosing, indications, and clinical considerations.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Correction
Rheumatology
Lykke M. Ornbjerg, Louise Linde, Stylianos Georgiadis, Simon H. Rasmussen, Ulf Lindstrom, Johan Askling, Brigitte Michelsen, Daniela Di Giuseppe, Johan K. Wallman, Karel Pavelka, Jakub Zavada, Michael J. Nissen, Gareth T. Jones, Heikki Relas, Laura Pirila, Matija Tomsic, Ziga Rotar, Arni Jon Geirsson, Bjorn Gudbjornsson, Eirik K. Kristianslund, Irene van der Horst-Bruinsma, Anne Gitte Loft, Karin Laas, Florenzo Iannone, Addolorata Corrado, Adrian Ciurea, Maria J. Santos, Helena Santos, Catalin Codreanu, Nurullah Akkoc, Ozgul S. Gunduz, Bente Glintborg, Mikkel Ostergaard, Merete Lund Hetland
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2023)
Article
Cell Biology
Morten A. A. Nielsen, Ditte Koster, Akul Y. Y. Mehta, Kristian Stengaard-Pedersen, Pierre Busson, Peter Junker, Kim Horslev-Petersen, Merete Lund Hetland, Mikkel ostergaard, Malene Hvid, Hakon Leffler, Tue W. W. Kragstrup, Richard D. D. Cummings, Bent Deleuran
Summary: This study evaluated the clinical and pathogenic aspects of Gal-9 in rheumatoid arthritis (RA) and found that it plays a role in modulating synovial FLS activities and maintaining subclinical disease activity.
Article
Rheumatology
Rasmus Westermann, Rene Lindholm Cordtz, Kirsten Duch, Lene Mellemkjaer, Merete Lund Hetland, Andrea Michelle Burden, Lene Dreyer
Summary: This study examined the risk of first primary cancer in patients with rheumatoid arthritis (RA) treated with janus kinase inhibitors (JAKi) compared to those treated with biologic disease-modifying antirheumatic drugs (bDMARDs) in a real-world setting. The results showed that JAKi treatment was not associated with a statistically significant increased risk of first primary cancer compared to bDMARDs treatment in RA patients.
Article
Immunology
Matthew L. L. Wright, Dana E. E. Goin, Mette Kiel Smed, Nicholas P. P. Jewell, J. Lee Nelson, Jorn Olsen, Merete Lund Hetland, Vibeke Zoffmann, Damini Jawaheer
Summary: This study investigated the systemic expression changes in protein-coding genes and long non-coding RNAs during and after pregnancy compared to before pregnancy in healthy women. The results showed that immune-related genes demonstrated time-dependent expression changes during pregnancy, including over-expression of neutrophil-related genes and under-expression of numerous immunoglobulin genes. The estimated cell type proportions revealed an increase in neutrophils during pregnancy. These findings provide insights into normal term pregnancy and can serve as reference for abnormal pregnancies and autoimmune diseases that improve or worsen during pregnancy.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Public, Environmental & Occupational Health
Kristina Laugesen, Jonas Mengel-From, Kaare Christensen, Jorn Olsen, David M. Hougaard, Lasse Boding, Anja Olsen, Christian Erikstrup, Merete Lund Hetland, Estrid Hogdall, Alisa Kjaergaard, Erik Sorensen, Anja Brugmann, Eva Rabing Brix Petersen, Ivan Brandslund, Borge Nordestgaard, Gorm B. Jensen, Nils Skajaa, Frederikke Schonfeldt Troelsen, Cecilia Hvitfeldt Fuglsang, Lise Skovgaard Svingel, Henrik T. Sorensen
Summary: Denmark has a rich source of biobanks and a comprehensive healthcare system, which allows for the integration of biological specimens with clinical and demographic data for biobank research. This can contribute to a better understanding of disease etiology and personalized medicine.
CLINICAL EPIDEMIOLOGY
(2023)
Review
Oncology
Gunhild Nynke Thomsen, Mette Niemann Christoffersen, Hanne Merete Lindegaard, Jesper Romhild Davidsen, Gitte Nyvang Hartmeyer, Kristian Assing, Charlotte G. Mortz, Raquel Martin-Iguacel, Michael Boe Moller, Anette Drohse Kjeldsen, Troels Havelund, Daniel El Fassi, Sigurd Broesby-Olsen, Michael Maiborg, Sofie Lock Johansson, Christen Lykkegaard Andersen, Hanne Vestergaard, Ole Weis Bjerrum
Summary: Patients with increased eosinophilic granulocytes often pose a clinical challenge due to the varied causes and symptoms associated with eosinophilia. A thorough medical history and specific tests are necessary for accurate diagnosis and personalized treatment. Referral to a multidisciplinary team in a hematology department is recommended for patients without a clear diagnosis or inadequate treatment response.
FRONTIERS IN ONCOLOGY
(2023)
Article
Rheumatology
Nanna S. Schmidt, Viktoria Fana, Mads Ammitzboll Danielsen, Hanne M. Lindegaard, Anne Voss, Hans Christian Horn, John B. Knudsen, Keld-Erik Byg, Melanie Birger Morillon, Soren Andreas Just, Uffe M. Dohn, Lene Terslev
Summary: The objective of this pilot study was to assess the impact of a salivary gland ultrasound atlas on scoring parenchymal changes in Sjogren's syndrome. The reliability of the scoring system was evaluated, and the use of the atlas improved both intra- and inter-reader reliability.
CLINICAL RHEUMATOLOGY
(2023)
Article
Rheumatology
Louise Linde, Lykke Midtboll Ornbjerg, Cecilie Heegaard Brahe, Johan Karlsson Wallman, Daniela Di Giuseppe, Jakub Zavada, Isabel Castrejon, Federico Diaz-Gonzalez, Ziga Rotar, Matija Tomsic, Bente Glintborg, Bjorn Gudbjornsson, Arni Jon Geirsson, Brigitte Michelsen, Eirik Klami Kristianslund, Maria Jose Santos, Anabela Barcelos, Dan Nordstrom, Kari K. Eklund, Adrian Ciurea, Michael Nissen, Servet Akar, Lise Hejl Hyldstrup, Niels Steen Krogh, Merete Lund Hetland, Mikkel Ostergaard
Summary: This study investigated the real-world effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) and its association with treatment line and reasons for withdrawal. The results showed similar drug retention rates for the second and third TNFi, but lower remission rates for the third TNFi. Additionally, higher remission rates were observed for the second TNFi if the withdrawal reason from the preceding TNFi was adverse events (AE).
Article
Rheumatology
Helga Westerlind, Bente Glintborg, Hilde Berner Hammer, Saedis Saevarsdottir, Niels Steen Krogh, Merete Lund Hetland, Ellen-Margrethe Hauge, Isabel Martinez Tejada, Joseph Sexton, Johan Askling
Summary: This study aims to describe how data harmonization can be achieved in rheumatoid arthritis (RA) and found that the proportion of patients reaching remission in RA treatment is low.
Article
Rheumatology
Alyssa Dominique, Merete Lund Hetland, Axel Finckh, Jacques-Eric Gottenberg, Florenzo Iannone, Roberto Caporali, Tzuyung Douglas Kou, Dan Nordstrom, Maria Victoria Hernandez, Carlos Sanchez-Piedra, Fernando Sanchez-Alonso, Karel Pavelka, T. Christopher Bond, Teresa A. Simon
Summary: This study analyzed the safety profile of abatacept in patients with rheumatoid arthritis, finding that the risk of infection and malignancy varied among different regions but overall there were no new or increased risks compared to previous studies.
ARTHRITIS RESEARCH & THERAPY
(2023)
Article
Rheumatology
Janni Maria Pedersen, Aida Solhoj Hansen, Caecilie Skejo, Kristian Juul-Madsen, Peter Junker, Kim Horslev-Petersen, Merete Lund Hetland, Kristian Stengaard-Pedersen, Mikkel ostergaard, Bjarne Kuno Moller, Lene Dreyer, Ellen-Margrethe Hauge, Malene Hvid, Stinne Greisen, Bent Deleuran
Summary: This study investigated the role of lymphocyte activation gene-3 (LAG-3) as a serological marker and mediator in the pathogenesis of rheumatoid arthritis (RA). The results showed increased levels of LAG-3 in both early and chronic RA patients, particularly in the inflamed joint. LAG-3 plays a biological role in reducing inflammatory cytokine production in chronic RA, and this function is not affected by Gal-3 interference. Our findings suggest that LAG-3 is a multifaceted regulator of inflammation in early and chronic RA.
ARTHRITIS RESEARCH & THERAPY
(2023)
Article
Rheumatology
Tanja Thomsen, Mette Aadahl, Merete Lund Hetland, Bente Appel Esbensen
Summary: A higher proportion of rheumatoid arthritis patients are physically inactive. Lack of consistent physical activity guidance from health professionals may be a barrier. This study explores patients' perspectives on current and future guidance and emphasizes the importance of integrated physical activity focus in rheumatology clinics, with adequate training for health professionals.
RHEUMATOLOGY INTERNATIONAL
(2023)